An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Diroximel Fumarate (BIIB098) in Chinese and Caucasian Adult Healthy Participants
Latest Information Update: 07 Jul 2022
At a glance
- Drugs Diroximel-fumarate (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Biogen
- 01 Jul 2022 Status changed from recruiting to completed.
- 05 May 2022 Planned End Date changed from 31 Mar 2022 to 1 Jun 2022.
- 05 May 2022 Planned primary completion date changed from 31 Mar 2022 to 1 Jun 2022.